METASTRON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METASTRON is an injectable pharmaceutical product approved in 1993 by Q BioMed. The specific mechanism of action and indication are not publicly disclosed in available data, limiting clinical context.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting transition planning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is not actively hiring; it represents a mature, stable portfolio asset rather than a growth opportunity. Career visibility is limited unless you are managing the LOE transition or defending market share.
Brand ManagerField Sales Representative
Worked on METASTRON at Q BioMed? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.